Skip to main content
Premium Trial:

Request an Annual Quote

Shares in Ciphergen Up 5 Percent on Sanofi-Aventis Deal

NEW YORK, Feb. 7 (GenomeWeb News) - Shares of Ciphergen were trading up $.08, or 5.06 percent, at $1.66 in afternoon trade following news of an alliance with Sanofi-Aventis.


As GenomeWeb News reported this morning, Ciphergen said it  extended a deal with Sanofi-Aventis to discover, validate, and identify biomarkers for a pre-clinical oncology drug efficacy study.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.